| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA935: Secukinumab for treating moderate to severe hidradenitis suppurativa |
|
Medicine details |
|
| Medicine name | secukinumab (Cosentyx®) |
| Formulation | subcutaneous injection |
| Reference number | 4318 |
| Indication | Treatment of hidradenitis suppurativa in adults with an inadequate response to conventional systemic HS therapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 20/10/2023 |
| NICE guidance | TA935: Secukinumab for treating moderate to severe hidradenitis suppurativa |